Altamir - Registration Document 2016

20 / 182

FINANCIAL AND LEGAL INFORMATION 1 Presentation and history of the Company
Year of
investment
Percentage
interest in the
underlying
operating
company
Residual cost
in €k
Stage of
development
TMT (Technology – Media – Telecom)
Marlink (1a) (2) 2016 27.30% 59,063 LBO
Altran Technologies* (3) 2008 7.06% 42,966 Growth capital
InfoVista (1a) (2) 2016 21.09% 39,071 LBO
Melita (1a) 2016 28.89% 33,911 LBO
Gfi Informatique* (3) 2007 7.53% 24,568 LBO
Nowo/Oni (1a) 2016 35.30% 20,575 LBO
Vocalcom (1a) 2011 17.10% 11,505 Growth capital
Exact Software (1b) 2015 0.96% 3,183 LBO
Engineering Ingegneria Informatica (1b) 2016 0.51% 2,554 LBO
Duck Creek Technologies (1b) 2016 0.57% 2,335 LBO
EVRY (1b) 2015 0.72% 1,664 LBO
GlobalLogic (1b) 2013 0.97% 1,357 LBO
Zensar* (1b) 2015 0.22% 1,126 LBO
243,878
1.2.3 ALTAMIR PORTFOLIO
At 31 December 2016
HEALTHCARE
Unilabs (3) (4) 2007 5.48% 22,548 LBO
Amplitude Surgical* (1a) 2011 13.42% 14,041 LBO
One Call Care Management (1b) 2013 0.33% 3,619 LBO
Invent Neurax (1b) 2016 0.91% 2,875 LBO
Vyaire Medical (1b) 2016 0.48% 2,085 LBO
Genex (1b) 2014 0.33% 321 LBO
Ideal Protein (1b) 2015 0.63% 151 LBO
45,639
(1) Investments via the Apax funds
(1a) via the Apax France VIII and Apax France IX funds
(1b) via the Apax VIII LP and Apax IX LP funds
(2) Co-investments (alongside the Apax France VIII and Apax France IX funds)
(3) Direct investments (legacy portfolio)
(4) Divestiture of Altamir’s direct investment and new investment in Unilabs via the Apax IX LP fund finalised in February 2017
* Listed company.
20 REGISTRATION DOCUMENT 1 ALTAMIR 2016